CXCL13 生物标志物在原发性干燥综合征合并腮腺非霍奇金淋巴瘤患者中的诊断作用。
Diagnostic role of CXCL13 biomarker in primary Sjogren's syndrome patients with parotid non-Hodgkin's lymphoma complication.
机构信息
2nd Internal Medicine Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, Romania.
2nd Internal Medicine Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, Romania.
出版信息
Med Clin (Barc). 2023 Jun 9;160(11):484-488. doi: 10.1016/j.medcli.2023.01.023. Epub 2023 Mar 31.
INTRODUCTION
Serum biomarkers are important predictive factors for development of parotid non-Hodgkin's lymphoma (NHL) complication in primary Sjogren's syndrome (pSS) patients. The aim was to evaluate the diagnostic accuracy of serum CXCL13 chemokine in pSS patients with parotid NHL complication.
MATERIAL AND METHODS
Serum CXCL13 chemokine was assessed in 33 patients with pSS [7 with parotid NHL complication (pSS+NHL subgroup) and 26 without NHL (pSS-NHL subgroup)] and 30 healthy subjects.
RESULTS
The serum CXCL13 levels in pSS+NHL subgroup [175.2 (107.9-220.4) pg/ml] were significantly higher comparing to the healthy subjects group (p=0.018) and the pSS-NHL subgroup (p=0.048). A cut-off value of 123.45pg/ml (Se=71.4%, Sp=80.8%, AUROC=0.747) was established for parotid lymphoma diagnosis.
CONCLUSION
The serum CXCL13 biomarker could be considered a valuable tool for the diagnosis of parotid NHL complication in pSS patients.
简介
血清生物标志物是非霍奇金淋巴瘤（NHL）并发症在原发性干燥综合征（pSS）患者中发展的重要预测因素。本研究旨在评估血清趋化因子 CXCL13 在伴腮腺 NHL 并发症的 pSS 患者中的诊断准确性。
材料和方法
评估了 33 例 pSS 患者[7 例伴腮腺 NHL 并发症（pSS+NHL 亚组）和 26 例无 NHL（pSS-NHL 亚组）]和 30 名健康受试者的血清趋化因子 CXCL13 水平。
结果
pSS+NHL 亚组的血清 CXCL13 水平[175.2（107.9-220.4）pg/ml]明显高于健康受试者组（p=0.018）和 pSS-NHL 亚组（p=0.048）。确定了 123.45pg/ml 的截值（Se=71.4%，Sp=80.8%，AUROC=0.747）用于诊断腮腺淋巴瘤。
结论
血清 CXCL13 生物标志物可被视为诊断 pSS 患者腮腺 NHL 并发症的有价值工具。
Zotero 插件